 Stanca Birlea
Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitiligo | 23 | 2020 | 75 | 7.950 |
Why?
| | Melanocytes | 11 | 2020 | 66 | 4.500 |
Why?
| | Ultraviolet Therapy | 4 | 2020 | 20 | 2.500 |
Why?
| | Skin Pigmentation | 4 | 2020 | 43 | 1.770 |
Why?
| | Hair Follicle | 5 | 2020 | 52 | 1.760 |
Why?
| | Stem Cells | 3 | 2017 | 559 | 1.250 |
Why?
| | Genetic Predisposition to Disease | 11 | 2016 | 2275 | 0.850 |
Why?
| | Regenerative Medicine | 3 | 2019 | 46 | 0.770 |
Why?
| | Adult Stem Cells | 1 | 2020 | 35 | 0.740 |
Why?
| | Laser Capture Microdissection | 2 | 2017 | 26 | 0.740 |
Why?
| | Bimatoprost | 1 | 2019 | 3 | 0.710 |
Why?
| | Autoimmune Diseases | 5 | 2016 | 398 | 0.710 |
Why?
| | beta Catenin | 2 | 2020 | 219 | 0.700 |
Why?
| | Guided Tissue Regeneration | 1 | 2019 | 14 | 0.700 |
Why?
| | Janus Kinase Inhibitors | 1 | 2019 | 10 | 0.700 |
Why?
| | Alopecia Areata | 1 | 2019 | 11 | 0.700 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 21 | 0.630 |
Why?
| | Regeneration | 2 | 2017 | 165 | 0.620 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2017 | 9 | 0.620 |
Why?
| | Genes, MHC Class II | 2 | 2013 | 72 | 0.540 |
Why?
| | Vitamin D | 2 | 2009 | 354 | 0.520 |
Why?
| | Skin | 2 | 2017 | 657 | 0.460 |
Why?
| | Autoimmunity | 2 | 2017 | 831 | 0.460 |
Why?
| | Forkhead Transcription Factors | 2 | 2010 | 182 | 0.440 |
Why?
| | Tretinoin | 1 | 2013 | 116 | 0.430 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 381 | 0.420 |
Why?
| | Polymorphism, Single Nucleotide | 9 | 2013 | 2062 | 0.400 |
Why?
| | Keratoacanthoma | 1 | 2010 | 3 | 0.380 |
Why?
| | Cimetidine | 1 | 2010 | 16 | 0.380 |
Why?
| | RNA | 1 | 2016 | 833 | 0.370 |
Why?
| | Romania | 6 | 2009 | 16 | 0.370 |
Why?
| | Histamine H2 Antagonists | 1 | 2010 | 31 | 0.360 |
Why?
| | Chromosomes, Human, Pair 6 | 1 | 2009 | 47 | 0.360 |
Why?
| | Signal Transduction | 3 | 2020 | 4709 | 0.350 |
Why?
| | Genome-Wide Association Study | 6 | 2016 | 1323 | 0.350 |
Why?
| | Receptors, Calcitriol | 2 | 2008 | 56 | 0.350 |
Why?
| | Calcium-Binding Proteins | 1 | 2009 | 217 | 0.320 |
Why?
| | Case-Control Studies | 6 | 2016 | 3171 | 0.310 |
Why?
| | Keratinocytes | 2 | 2020 | 227 | 0.300 |
Why?
| | Vitamins | 1 | 2008 | 158 | 0.290 |
Why?
| | Antigens, CD | 1 | 2009 | 460 | 0.280 |
Why?
| | Melanosis | 1 | 2006 | 14 | 0.280 |
Why?
| | Humans | 29 | 2020 | 118974 | 0.270 |
Why?
| | Apoptosis | 1 | 2013 | 2484 | 0.240 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1346 | 0.230 |
Why?
| | Cell Movement | 2 | 2019 | 896 | 0.220 |
Why?
| | Cytokines | 1 | 2010 | 1900 | 0.220 |
Why?
| | Transcription Factors | 1 | 2010 | 1570 | 0.220 |
Why?
| | Monophenol Monooxygenase | 2 | 2013 | 11 | 0.210 |
Why?
| | Melanins | 2 | 2013 | 22 | 0.200 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2020 | 50 | 0.190 |
Why?
| | rho GTP-Binding Proteins | 1 | 2020 | 65 | 0.180 |
Why?
| | Phototherapy | 1 | 2019 | 25 | 0.180 |
Why?
| | Cell Self Renewal | 1 | 2019 | 51 | 0.170 |
Why?
| | Cell Proliferation | 3 | 2015 | 2275 | 0.160 |
Why?
| | PUVA Therapy | 1 | 2017 | 6 | 0.150 |
Why?
| | Genotype | 5 | 2016 | 1882 | 0.140 |
Why?
| | Ligands | 2 | 2009 | 567 | 0.140 |
Why?
| | Melanoma | 3 | 2018 | 664 | 0.140 |
Why?
| | Phenotype | 2 | 2015 | 3003 | 0.140 |
Why?
| | Pedigree | 2 | 2008 | 485 | 0.140 |
Why?
| | PAX3 Transcription Factor | 1 | 2015 | 12 | 0.130 |
Why?
| | Paired Box Transcription Factors | 1 | 2015 | 40 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 409 | 0.130 |
Why?
| | Intramolecular Oxidoreductases | 1 | 2015 | 59 | 0.130 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2015 | 64 | 0.130 |
Why?
| | Epidermis | 1 | 2015 | 152 | 0.120 |
Why?
| | Middle Aged | 7 | 2020 | 27617 | 0.120 |
Why?
| | Microscopy, Phase-Contrast | 1 | 2013 | 19 | 0.120 |
Why?
| | Annexin A5 | 1 | 2013 | 24 | 0.120 |
Why?
| | Polymorphism, Genetic | 2 | 2008 | 642 | 0.120 |
Why?
| | Smad4 Protein | 1 | 2013 | 37 | 0.120 |
Why?
| | Spectrophotometry | 1 | 2013 | 52 | 0.120 |
Why?
| | Quantitative Trait Loci | 2 | 2016 | 324 | 0.110 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2009 | 3360 | 0.110 |
Why?
| | Catalase | 1 | 2013 | 123 | 0.110 |
Why?
| | Sri Lanka | 1 | 2013 | 12 | 0.110 |
Why?
| | Linkage Disequilibrium | 2 | 2010 | 273 | 0.110 |
Why?
| | HLA-DQ alpha-Chains | 1 | 2013 | 17 | 0.110 |
Why?
| | Administration, Topical | 1 | 2013 | 141 | 0.110 |
Why?
| | Bangladesh | 1 | 2013 | 39 | 0.110 |
Why?
| | Pakistan | 1 | 2013 | 74 | 0.110 |
Why?
| | India | 1 | 2013 | 141 | 0.110 |
Why?
| | ras Proteins | 1 | 2013 | 141 | 0.110 |
Why?
| | Adult | 6 | 2020 | 31512 | 0.110 |
Why?
| | HLA-DRB1 Chains | 1 | 2013 | 97 | 0.110 |
Why?
| | Biomedical Research | 1 | 2018 | 612 | 0.110 |
Why?
| | Magnetic Field Therapy | 1 | 2012 | 3 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2017 | 702 | 0.110 |
Why?
| | Skin Ulcer | 1 | 2012 | 15 | 0.100 |
Why?
| | Young Adult | 2 | 2020 | 10793 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2017 | 1323 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 339 | 0.100 |
Why?
| | Regulatory Factor X Transcription Factors | 1 | 2010 | 11 | 0.100 |
Why?
| | X-Box Binding Protein 1 | 1 | 2010 | 8 | 0.100 |
Why?
| | Female | 10 | 2020 | 61565 | 0.100 |
Why?
| | Genetic Loci | 1 | 2012 | 281 | 0.090 |
Why?
| | Prevalence | 2 | 2008 | 2326 | 0.090 |
Why?
| | Genetic Testing | 1 | 2013 | 389 | 0.090 |
Why?
| | Founder Effect | 1 | 2009 | 12 | 0.090 |
Why?
| | Animals | 5 | 2019 | 33381 | 0.090 |
Why?
| | Cell Survival | 1 | 2013 | 1047 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2013 | 336 | 0.090 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 618 | 0.090 |
Why?
| | Wound Healing | 1 | 2012 | 270 | 0.090 |
Why?
| | Major Histocompatibility Complex | 1 | 2010 | 220 | 0.090 |
Why?
| | Antioxidants | 1 | 2013 | 564 | 0.090 |
Why?
| | Odds Ratio | 2 | 2009 | 996 | 0.080 |
Why?
| | Phytotherapy | 1 | 2009 | 69 | 0.080 |
Why?
| | Genetic Linkage | 1 | 2009 | 321 | 0.080 |
Why?
| | CTLA-4 Antigen | 1 | 2009 | 86 | 0.080 |
Why?
| | Histones | 1 | 2013 | 552 | 0.080 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 22 | 1 | 2008 | 46 | 0.080 |
Why?
| | Aged | 3 | 2020 | 19657 | 0.080 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2013 | 610 | 0.080 |
Why?
| | Cell Differentiation | 1 | 2015 | 1753 | 0.080 |
Why?
| | Repressor Proteins | 1 | 2010 | 377 | 0.070 |
Why?
| | Adolescent | 2 | 2020 | 18480 | 0.070 |
Why?
| | Male | 7 | 2020 | 57801 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2007 | 190 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2020 | 9342 | 0.070 |
Why?
| | Child | 2 | 2020 | 19129 | 0.070 |
Why?
| | Skin Neoplasms | 1 | 2013 | 762 | 0.070 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 2006 | 64 | 0.070 |
Why?
| | Alleles | 1 | 2009 | 832 | 0.070 |
Why?
| | Rural Health | 1 | 2006 | 72 | 0.070 |
Why?
| | Cells, Cultured | 1 | 2013 | 4077 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2008 | 306 | 0.060 |
Why?
| | Mice | 2 | 2019 | 15520 | 0.060 |
Why?
| | Models, Statistical | 1 | 2009 | 636 | 0.060 |
Why?
| | DNA Primers | 1 | 2006 | 533 | 0.060 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2007 | 394 | 0.060 |
Why?
| | Time Factors | 1 | 2013 | 6412 | 0.050 |
Why?
| | Sex Factors | 1 | 2008 | 1781 | 0.050 |
Why?
| | Models, Biological | 1 | 2009 | 1715 | 0.050 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 989 | 0.050 |
Why?
| | DNA | 1 | 2006 | 1388 | 0.040 |
Why?
| | Pigmentation | 1 | 2018 | 58 | 0.040 |
Why?
| | Age of Onset | 2 | 2011 | 467 | 0.040 |
Why?
| | Gene Frequency | 2 | 2010 | 513 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2008 | 6561 | 0.040 |
Why?
| | Prospective Studies | 1 | 2008 | 6471 | 0.040 |
Why?
| | Risk Factors | 1 | 2009 | 9000 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2018 | 671 | 0.030 |
Why?
| | Child, Preschool | 1 | 2008 | 9491 | 0.030 |
Why?
| | Side-Population Cells | 1 | 2013 | 10 | 0.030 |
Why?
| | alpha Catenin | 1 | 2013 | 14 | 0.030 |
Why?
| | Pregnancy | 1 | 2006 | 5691 | 0.030 |
Why?
| | Cell Dedifferentiation | 1 | 2013 | 30 | 0.030 |
Why?
| | Sequence Deletion | 1 | 2013 | 171 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 245 | 0.030 |
Why?
| | Eye Color | 1 | 2012 | 4 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2013 | 237 | 0.030 |
Why?
| | Chromosomes, Human, Pair 15 | 1 | 2012 | 64 | 0.030 |
Why?
| | Carcinogenesis | 1 | 2013 | 182 | 0.030 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2013 | 176 | 0.030 |
Why?
| | Mice, Nude | 1 | 2013 | 663 | 0.030 |
Why?
| | Tumor Cells, Cultured | 1 | 2013 | 874 | 0.030 |
Why?
| | Mutation, Missense | 1 | 2013 | 300 | 0.030 |
Why?
| | RNA Interference | 1 | 2013 | 460 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2008 | 12978 | 0.020 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2010 | 51 | 0.020 |
Why?
| | Neovascularization, Physiologic | 1 | 2012 | 181 | 0.020 |
Why?
| | Family Health | 1 | 2010 | 201 | 0.020 |
Why?
| | Genetic Markers | 1 | 2010 | 348 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 3730 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2013 | 2025 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1167 | 0.020 |
Why?
| | NLR Proteins | 1 | 2007 | 7 | 0.020 |
Why?
| | Proportional Hazards Models | 1 | 2011 | 1125 | 0.020 |
Why?
| | Reference Standards | 1 | 2008 | 176 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3057 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 969 | 0.020 |
Why?
| | MicroRNAs | 1 | 2013 | 637 | 0.020 |
Why?
| | Genetic Variation | 1 | 2010 | 926 | 0.020 |
Why?
| | Inflammation | 1 | 2012 | 2566 | 0.010 |
Why?
|
|
Birlea's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|